

註一覽

- [1] Vincenzo Di Marzo and Fabiana Piscitelli, "The Endocannabinoid System and Its Modulation by Phytocannabinoids," *Neurotherapeutics* 12, no. 4 (2015) : 692–98, doi:10.1007/s13311-015-0374-6.
- [2] Daniel R. McDougale et al., "Anti-Inflammatory ω -3 Endocannabinoid Epoxides," *Proceedings of the National Academy of Sciences* 114, no. 30 (2017) , doi:10.1073/pnas.1610325114.
- [3] John M. McPartland et al., "Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions That Upregulate the Endocannabinoid System," *PLoS One* 9, no. 3 (2014) , doi:10.1371/journal.pone.0089566.
- [4] McPartland et al., "Care and Feeding."
- [5] Maria Morena et al., "Neurobiological Interactions between Stress and the Endocannabinoid System," *Neuropsychopharmacology* 41, no. 1 (2016) : 80–102, doi:10.1038/npp.2015.166.
- [6] Elsa Heyman et al., "Intense Exercise Increases Circulating Endocannabinoid and BDNF Levels in Humans—Possible Implications for Reward and Depression," *Psychoneuroendocrinology* 37, no. 6 (2012) : 844–51, doi:10.1016/j.psyneuen.2011.09.017.
- [7] Raymond Niesink et al., "Does Cannabidiol Protect Against Adverse Psychological Effects of THC?" *Frontiers in Psychiatry* 4, no.4 (2013) : 130, doi:10.3389/fpsy.2013.00130.
- [8] J. D. Wilkinson et al., "Medicinal Cannabis: Is Δ 9-Tetrahydrocannabinol Necessary for All Its Effects?" *Journal of Pharmacy and Pharmacology* 55, no. 12 (2004) : 1687–94, doi:10.1211/0022357022304.
- [9] Angélica Maria Sabogal-Guáqueta, Edison Osorio, and Gloria Patricia Cardona-Gómez, "Linalool Reverses Neuropathological and Behavioral Impairments in Old Triple Transgenic Alzheimers Mice," *Neuropharmacology* 102, (2016) : 111–20, doi:10.1016/j.neuropharm.2015.11.002.
- [10] A. L. Klauke et al., "The Cannabinoid CB2 Receptor-Selective Phytocannabinoid Beta-Caryophyllene Exerts Analgesic Effects in Mouse Models of Inflammatory and Neuropathic Pain," *European Neuropsychopharmacology* 24, no. 4 (2014) : 608–20, doi:10.1016/j.euroneuro.2013.10.008.
- [11] Amine Bahi et al., " β -Caryophyllene, a CB2 Receptor Agonist Produces Multiple Behavioral Changes Relevant to Anxiety and Depression in Mice," *Physiology & Behavior* 135, (2014) : 119–24, doi:10.1016/j.physbeh.2014.06.003.
- [12] T. G. do Vale et al., "Central Effects of Citral, Myrcene and Limonene, Constituents of Essential Oil Chemotypes from Lippia Alba (Mill.) N.E. Brown," *Phytomedicine* 9, no. 8 (2002) : 709–14.
- [13] V. S. Rao, A. M. Menezes, and G. S. Viana, "Effect of Myrcene on Nociception in Mice," *Journal of Pharmacy and Pharmacology* 42, no. 12 (1990) : 877–78, doi:10.1111/j.2042-7158.1990.tb07046.x.; L. I. Paula-Freire et al., "Evaluation of the Antinociceptive Activity Of Ocimum GratissimumL. (Lamiaceae) Essential Oil and Its Isolated Active Principles in Mice," *Phytotherapy Research* 27, no. 8 (2013) : 1220–24, doi:10.1002/ptr.4845.
- [14] Aline De Moraes Pultrini, Luciane Almeida Galindo, and Mirtes Costa, "Effects of the Essential Oil from Citrus Aurantium L. in Experimental Anxiety Models in Mice," *Life Sciences*

- 78, no. 15 (2006) : 1720–25, doi:10.1016/j.lfs.2005.08.004.
- [15]C. F. Zhang, Z. L. Yang, and J. B. Luo, "Effects of D-Limonene and L-Limonene on Transdermal Absorption of Ligustrazine Hydrochloride," *Yao Xue Xue Bao* 41, no. 8 (2006) : 772–77.
- [16]J. Sun, "D-Limonene: Safety and Clinical Applications," *Alternative Medicine Review* 12, no. 3 (2007) : 259–64.
- [17]R. L. Jirtle et al., "Increased Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor and Transforming Growth Factor Beta 1 Levels during Monoterpene-Induced Regression of Mammary Tumors," *Cancer Research* 53, no. 17 (1993) : 3849–52.
- [18]M. G. de Oliveira et al., " α -Terpineol Reduces Mechanical Hypernociception and Inflammatory Response," *Basic & Clinical Pharmacology & Toxicology* 111, no. 2 (2012) : 120–25, doi:10.1111/j.1742-7843.2012.00875.x.
- [19]R. H. L. Souza et al., "Gastroprotective Activity of α -Terpineol in Two Experimental Models of Gastric Ulcer in Rats," *DARU Journal of Pharmaceutical Sciences* 19, no. 4 (2011): 277–81.
- [20]Li Li et al., "Antibacterial Activity of α -Terpineol May Induce Morphostructural Alterations in *Escherichia Coli*," *Brazilian Journal of Microbiology* 45, no. 4 (2015) : 1409–13, doi:10.1590/s1517-83822014000400035.
- [21]J. L. Bicas et al., "Evaluation of the Antioxidant and Antiproliferative Potential of Bioflavors," *Food and Chemical Toxicology* 49, no. 7 (2011) : 1610–15, doi:10.1016/j.fct.2011.04.012.
- [22]A. J. Hampson et al., "Cannabidiol and (-) Δ 9-Tetrahydrocannabinol Are Neuroprotective Antioxidants," *Proceedings of the National Academy of Sciences* 95, no. 14 (1998) : 8268–73, doi:10.1073/pnas.95.14.8268.
- [23]Kerstin Iffland and Franjo Grotenhermen, "An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies," *Cannabis and Cannabinoid Research* 2, no. 1 (2017) : 139–54, doi:10.1089/can.2016.0034.
- [24]M. M. Bergamaschi et al., "Safety and Side Effects of Cannabidiol, a Cannabis Sativa Constituent," *Current Drug Safety* 6, no. 4 (2011): 237–49, doi:10.2174/157488611798280924.
- [25]Amanda Reiman, Mark Welty, and Perry Solomon, "Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report," *Cannabis and Cannabinoid Research* 2, no. 1 (2017) : 160–66, doi:10.1089/can.2017.0012.
- [26]Kevin F. Boehnke, Evangelos Litinas, and Daniel J. Clauw, "Medical Cannabis Use Is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients 252 HEALING with CBD with Chronic Pain," *The Journal of Pain* 17, no. 6 (2016): 739–44, doi:10.1016/j.jpain.2016.03.002.
- [27]Gustavo Gonzalez-Cuevas et al., "Unique Treatment Potential of Cannabidiol for the Prevention of Relapse to Drug Use: Preclinical Proof of Principle," *Neuropsychopharmacology* (2018) , doi:10.1038/s41386-018-0050-8.
- [28]Kerstin Iffland and Franjo Grotenhermen, "An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies," *Cannabis and Cannabinoid Research* 2, no. 1 (2017) : 139–54, doi:10.1089/can.2016.0034.
- [29]E. L. Gardner, "Endocannabinoid Signaling System and Brain Reward: Emphasis on Dopamine," *Pharmacology Biochemistry and Behavior* 81, no. 2 (2005) : 263–84, doi:10.1016/j.pbb.2005.01.032.

- [30] Daniel Liput et al., "Transdermal Delivery of Cannabidiol Attenuates Binge Alcohol-Induced Neurodegeneration in a Rodent Model of an Alcohol Use Disorder," *Pharmacology Biochemistry and Behavior* 111 (2013) : 120-127, doi:10.1016/j.pbb.2013.08.013.
- [31] Yuping Wang et al., "Cannabidiol Attenuates Alcohol-Induced Liver Steatosis, Metabolic Dysregulation, Inflammation and Neutrophil-Mediated Injury," *Scientific Reports* 7, no. 1 (2017) , doi:10.1038/s41598-017-10924-8.
- [32] Gustavo Gonzalez-Cuevas et al., "Unique Treatment Potential of Cannabidiol for the Prevention of Relapse to Drug Use: Preclinical Proof of Principle," *Neuropsychopharmacology* (2018) , doi:10.1038/s41386-018-0050-8.
- [33] Chandni Hindocha et al., "Cannabidiol Reverses Attentional Bias to Cigarette Cues in a Human Experimental Model of Tobacco Withdrawal," *Addiction*, May (2018) , doi:10.1111/add.14243.
- [34] Yasmin L. Hurd et al., "Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage," *Neurotherapeutics* 12, no. 4 (2015) : 807–15, doi:10.1007/s13311-015-0373-7.
- [35] Yanhua Ren et al., "Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances," *Journal of Neuroscience* 29, no. 47 (2010) : 14764–69, doi:10.1523/jneurosci.4291-09.2009.
- [36] Thangavelu Soundara Rajan et al., "Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked with Amyotrophic Lateral Sclerosis," *Journal of Cellular Biochemistry* 118, no. 4 (2016) : 819–28, doi:10.1002/jcb.25757.
- [37] Gregory T. Carter et al., "Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials," *American Journal of Hospice and Palliative Medicine* 27, no. 5 (2010) : 347–56, doi:10.1177/1049909110369531.
- [38] Emanuela Mazzon and Sabrina Giacoppo, "Can Cannabinoids Be a Potential Therapeutic Tool in Amyotrophic Lateral Sclerosis?" *Neural Regeneration Research* 11, no. 12 (2016) : 1896–99, doi:10.4103/1673-5374.197125.
- [39] Rajan et al., "Gingival Stromal Cells as an In Vitro Model," 819–28.
- [40] A. Calignano et al., "Bidirectional Control of Airway Responsiveness by Endogenous Cannabinoids," *Nature* 408, no. 6808 (2000) : 96–101.
- [41] Sumner Burstein, "Cannabidiol (CBD) and Its Analogs: a Review of Their Effects on Inflammation," *Bioorganic & Medicinal Chemistry* 23, no. 7 (2015) : 1377–85, doi:10.1016/j.bmc.2015.01.059.
- [42] Francieli Vuolo et al., "Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma," *Mediators of Inflammation* 2015, (May 2015) . doi:10.1155/2015/538670.
- [43] C. Földy, R. C. Malenka, and T. C. Südhof, "Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling," *Neuron* 78, no. 3 (2013) : 498–509, doi:10.1016/j.neuron.2013.02.036.
- [44] Dario Siniscalco et al., "Cannabinoid Receptor Type 2, but Not Type 1, Is Up-Regulated in Peripheral Blood Mononuclear Cells of 254 HEALING with CBD Children Affected by Autistic Disorders," *Journal of Autism and Developmental Disorders* 43, no. 11 (2013) : 2686–95, doi:10.1007/s10803-013-1824-9.
- [45] V. M. Doenni et al., "Deficient Adolescent Social Behavior Following Early-Life Inflammation

- Is Ameliorated by Augmentation of Anandamide Signaling," *Brain, Behavior, and Immunity* 58 (July 2016) : 237–47, doi:10.1016/j.bbi.2016.07.152.
- [46]Georgia Watt and Tim Karl, "In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimers Disease," *Frontiers in Pharmacology* 8 (February 2017) : 20, doi:10.3389/fphar.2017.00020.
- [47] A. M. Martín-Moreno et al., "Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimers Disease," *Molecular Pharmacology* 79, no. 6 (2011) : 964–73, doi:10.1124/mol.111.071290.
- [48]David Cheng et al., "Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimers Disease Transgenic Mice," *Journal of Alzheimers Disease* 42, no. 4 (2014) : 1383–96, doi:10.3233/jad-140921.
- [49]Melanie-Jayne R. Howes and Elaine Perry, "The Role of Phytochemicals in the Treatment and Prevention of Dementia," *Drugs & Aging* 28, no. 6 (2011) : 439–68, doi:10.2165/11591310-000000000-00000.
- [50]Peter Strohecker-Huehner, Gisela Skopp, and Tainer Mattern, "Cannabis Improves Symptoms of ADHD," *Cannabinoids* 3, no. 1 (2008) : 1–3.
- [51]Maura Castelli et al., "Loss of Striatal Cannabinoid CB1 Receptor Function in Attention-Deficit/Hyperactivity Disorder Mice with Point-Mutation of the Dopamine Transporter," *European Journal of Neuroscience* 43, no. 9 (2011) : 1369-1377, doi:10.1111/j.1460-9568.2011.07876.x.
- [52]Esther M. Blessing et al., "Cannabidiol as a Potential Treatment for Anxiety Disorders," *Neurotherapeutics* 12, no. 4 (2015) : 825–36, doi:10.1007/s13311-015-0387-1.
- [53]Raquel Linge et al., "Cannabidiol Induces Rapid-Acting Antidepressant-like Effects and Enhances Cortical 5-HT/Glutamate Neurotransmission: Role of 5-HT1A Receptors," *Neuropharmacology* 103, (December 2015) : 16–26, doi:10.1016/j.neuropharm.2015.12.017.
- [54]Alline C. Campos et al., "The Anxiolytic Effect of Cannabidiol on Chronically Stressed Mice Depends on Hippocampal Neurogenesis: Involvement of the Endocannabinoid System," *The International Journal of Neuropsychopharmacology* 16, no. 6 (2013) : 1407–19, doi:10.1017/s1461145712001502.
- [55]José Alexandre S. Crippa et al., "Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: a Preliminary Report," *Journal of Psychopharmacology* 25, no. 1 (2010) : 121–30, doi:10.1177/0269881110379283.
- [56]Mateo M. Bergamaschi et al., "Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients," *Neuropsychopharmacology* 36, no. 6 (2011) : 1219–26.
- [57]Leonardo B. M. Resstel et al., "5-HT1A Receptors Are Involved in the Cannabidiol-Induced Attenuation of Behavioural and Cardiovascular Responses to Acute Restraint Stress in Rats," *British Journal of Pharmacology* 156, no. 1 (2009) : 181–88, doi:10.1111/j.1476-5381.2008.00046.x.
- [58]Mark A. Lewis, Ethan B. Russo, and Kevin M. Smith, "Pharmacological Foundations of Cannabis Chemovars," *Planta Medica* 84, no. 4 (2017) : 225–33, doi:10.1055/s-0043-122240.
- [59]Ethan B. Russo, "Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects," *British Journal of Pharmacology* 163, no. 7 (2011) : 1344–64, doi:10.1111/j.1476-5381.2011.01238.x.

- [60] Sumner Burstein, "Cannabidiol (CBD) and Its Analogs: a Review of Their Effects on Inflammation," *Bioorganic & Medicinal Chemistry* 23, no. 7 (2015) : 1377–85, doi:10.1016/j.bmc.2015.01.059.
- [61] Carmen La Porta et al., "Involvement of the Endocannabinoid System in Osteoarthritis Pain," *European Journal of Neuroscience* 39, no. 3 (2014) : 485–500, doi:10.1111/ejn.12468.
- [62] D. C. Hammell et al., "Transdermal Cannabidiol Reduces Inflammation and Pain-Related Behaviours in a Rat Model of Arthritis," *European Journal of Pain* 20, no. 6 (2015) : 936–48, doi:10.1002/ejp.818.
- [63] A. M. Malfait et al., "The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine Collagen-Induced Arthritis," *Proceedings of the National Academy of Sciences* 97, no. 17 (2000) : 9561–66, doi:10.1073/pnas.160105897.
- [64] D. R. Blake et al., "Preliminary Assessment of the Efficacy, Tolerability and Safety of a Cannabis-Based Medicine (Sativex) in the Treatment of Pain Caused by Rheumatoid Arthritis," *Rheumatology* 45, no. 1 (2005) : 50–52, doi:10.1093/rheumatology/kei183.
- [65] George W. Booz, "Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress," *Free Radical Biology and Medicine* 51, no. 5 (2011) : 1054–61, doi:10.1016/j.freeradbiomed.2011.01.007.
- [66] P. Pacher, S. B atkai, and G. Kunos, "The Endocannabinoid System as an Emerging Target of Pharmacotherapy," *Pharmacological Reviews* 58, no. 3 (2008) : 389–462, doi:10.1124/pr.58.3.2.
- [67] G. A. Cabral and A. Staab, "Effects on the Immune System," *Handbook of Experimental Pharmacology Cannabinoids*, no. 168 (2005) : 385–423, doi:10.1007/3-540-26573-2_13.
- [68] Prakash Nagarkatti et al., "Cannabinoids as Novel Anti-Inflammatory Drugs," *Future Medicinal Chemistry* 1, no. 7 (2009) : 1333–49, doi:10.4155/fmc.09.93.
- [69] Lola Weiss et al., "Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice," *Neuropharmacology* 54, no. 1 (2009) : 244–49, doi:10.1016/j.neuropharm.2007.06.029.
- [70] Paola Massi et al., "Cannabidiol as Potential Anticancer Drug," *British Journal of Clinical Pharmacology* 75 no. 2 (2013) : 303–12, doi:10.1111/j.1365-2125.2012.04298.x.
- [71] Massi, "Cannabidiol as Potential Anticancer Drug," 303–12.
- [72] M. Solinas et al., "Cannabidiol Inhibits Angiogenesis by Multiple Mechanisms," *British Journal of Pharmacology* 167, no. 6 (2012) : 1218–31, doi:10.1111/j.1476-5381.2012.02050.x.
- [73] A.I. Fraguas-Sanchez, A. Fernandez-Carballido, and A.I. Torres-Suarez, "Phyto-, endo-, and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas," *Expert Opinion on Investigational Drugs* 25, no. 11 (2016) : 1311–1323, doi:10.1080/13543784.2016.1236913.
- [74] Sean D. McAllister, Liliana Soroceanu, and Pierre-Yves Desprez, "The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids," *Journal of Neuroimmune Pharmacology* 10, no. 2 (2015) : 255–67, doi:10.1007/s11481-015-9608-y.
- [75] Katherine Ann Scott et al., "Enhancing the Activity of Cannabidiol and Other Cannabinoids In Vitro Through Modifications to Drug Combinations and Treatment Schedules," *Anticancer Research* 33, no. 10 (2013) : 4373–80.
- [76] Dereck T. Wade et al., "A Preliminary Controlled Study to Determine Whether Whole-Plant Cannabis Extracts Can Improve Intractable Neurogenic Symptoms," *Clinical Rehabilitation* 17, no. 1 (2003) : 21–29, doi:10.1191/0269215503cr581oa.

- [77] Marcelo Kwiatkoski, Francisco Silveira Guimarães, and Elaine Del-Bel, "Cannabidiol-Treated Rats Exhibited Higher Motor Score After Cryogenic Spinal Cord Injury," *Neurotoxicity Research* 21, no. 3 (2011) : 271–80, doi:10.1007/s12640-011-9273-8.
- [78] David Fernández-López et al., "Cannabinoids: Well-Suited Candidates for the Treatment of Perinatal Brain Injury," *Brain Sciences* 3, no. 3 (2013) : 1043–59, doi:10.3390/brainsci3031043.
- [79] Matthew N. Hill et al., "Regional Alterations in the Endocannabinoid System in an Animal Model of Depression: 258 HEALING with CBD Effects of Concurrent Antidepressant Treatment," *Journal of Neurochemistry* 106, no. 6 (2008) : 2322–36, doi:10.1111/j.1471-4159.2008.05567.x.
- [80] Raquel Linge et al., "Cannabidiol Induces Rapid-Acting Antidepressant-like Effects and Enhances Cortical 5-HT/Glutamate Neurotransmission: Role of 5-HT1A Receptors," *Neuropharmacology* 103, (December 2015) : 16–26, doi:10.1016/j.neuropharm.2015.12.017.
- [81] Béla Horváth et al., "The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications," *The American Journal of Pathology* 180, no. 2 (2012): 432–42, doi:10.1016/j.ajpath.2011.11.003.
- [82] Khalid A. Jadoon et al., "Efficacy and Safety of Cannabidiol and Tetrahydrocannabinol on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study," *Diabetes Care* 39, no. 10 (2016) :1777–86, doi:10.2337/dc16-0650.
- [83] Mohanraj Rajesh et al., "Cannabidiol Attenuates High Glucose-Induced Endothelial Cell Inflammatory Response and Barrier Disruption," *American Journal of Physiology-Heart and Circulatory Physiology* 293, no. 1 (2007) : H610–H619, doi:10.1152/ajpheart.00236.2007.
- [84] Lola Weiss et al., "Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice," *Neuropharmacology* 54, no. 1 (2009) : 244–49, doi:10.1016/j.neuropharm.2007.06.029.
- [85] L. Weiss et al., "Cannabidiol Arrests," 2006.
- [86] Azza B. El-Remessy et al., "Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes," *The American Journal of Pathology* 168, no. 1 (2006): 235–44, doi:10.2353/ajpath.2006.050500.
- [87] Brian Walitt et al., "Cannabinoids for Fibromyalgia," *Cochrane Database of Systematic Reviews* 7, (July 2016) , doi:10.1002/14651858.cd011694.pub2.
- [88] George Habib and Suheil Artul, "Medical Cannabis for the Treatment of Fibromyalgia," *JCR: Journal of Clinical Rheumatology* 24, no. 5 (2018) : 255–58, doi:10.1097/rhu.0000000000000702.
- [89] Angelo A. Izzo and Keith B. Sharkey, "Cannabinoids and the Gut: New Developments and Emerging Concepts," *Pharmacology & Therapeutics* 126, no. 1 (2010) : 21–38, doi:10.1016/j.pharmthera.2009.12.005.
- [90] Haidar Shamran et al., "Fatty Acid Amide Hydrolase (FAAH) Blockade Ameliorates Experimental Colitis by Altering MicroRNA Expression and Suppressing Inflammation," *Brain, Behavior, and Immunity* 59 (June 2016) : 10–20, doi:10.1016/j.bbi.2016.06.008.
- [91] R. Capasso et al., "Cannabidiol, Extracted From Cannabis sativa, Selectively Inhibits Inflammatory Hypermotility in Mice," *British Journal of Pharmacology* 154, no. 5 (2008) : 1001–8, doi:10.1038/bjp.2008.177.
- [92] Giuseppe Esposito et al., "Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview,"

- Phytotherapy Research* 27, no. 5 (2012) : 633–36, doi:10.1002/ptr.4781.
- [93]J. M. Jamontt et al., “The Effects of Δ 9-Tetrahydrocannabinol and Cannabidiol Alone and in Combination on Damage, Inflammation Andin Vitromotility Disturbances in Rat Colitis,” *British Journal of Pharmacology* 160, no. 3 (2010) : 712–23, doi:10.1111/j.1476-5381.2010.00791.x.
- [94]Daniele De Filippis et al., “Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis,” *PLoS ONE* 6, no. 12 (2011) , doi:10.1371/journal.pone.0028159.
- [95]Ethan B. Russo, “Clinical Endocannabinoid Deficiency (CECD) : Can This Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and Other Treatment-Resistant Conditions?” *Neuro Endocrinology Letters* 29, no. 2 (2008) : 192–200.
- [96]Russo, “Clinical Endocannabinoid Deficiency,” 192–200.
- [97]Ethan B. Russo, “Cannabinoids in the Management of Difficult to Treat Pain,” *Therapeutics and Clinical Risk Management* 4, no. 1 (2008) : 245–59, doi:10.2147/tcrm.s1928.
- [98]Rosaria Greco et al., “Activation of CB2 Receptors as a Potential Therapeutic Target for Migraine: Evaluation in an Animal Model,” *The Journal of Headache and Pain* 15, no. 1 (2014) : 14, doi:10.1186/1129-2377-15-14.
- [99]“Cannabinoids Suitable for Migraine Prevention,” EAN, EAN, European Academy of Neurology, (2017) https://www.ean.org/amsterdam2017/fileadmin/user_upload/E-EAN_2017_-_Cannabinoids_in_migraine_-_FINAL.pdf.
- [100]David Baker et al., “The Biology That Underpins the Therapeutic Potential of Cannabis-Based Medicines for the Control of Spasticity in Multiple Sclerosis,” *Multiple Sclerosis and Related Disorders* 1, no. 2 (2012) : 64–75, doi:10.1016/j.msard.2011.11.001.
- [101]S. Giacoppo et al., “Purified Cannabidiol, the Main Non-Psychotropic Component of Cannabis Sativa, Alone, Counteracts Neuronal Apoptosis in Experimental Multiple Sclerosis,” *European Review for Medical and Pharmacological Sciences* 19, no. 24 (2015) : 4906–19.
- [102]Varda Mei-Tal, Sanford Meyerowitz, and George L. Engel, “The Role of Psychological Process in a Somatic Disorder: Multiple Sclerosis,” *Psychosomatic Medicine* 32, no. 1 (1970) : 67–86, doi:10.1097/00006842-197001000-00006.
- [103]K. D. Ackerman et al., “Stressful Life Events Precede Exacerbations of Multiple Sclerosis,” *Psychosomatic Medicine* 64, no. 6 (2002) : 916–20, doi:10.1097/01.psy.0000038941.33335.40.
- [104]E. M. Rock et al., “Cannabidiol, a Non-Psychotropic Component of Cannabis, Attenuates Vomiting and Nausea-like Behaviour via Indirect Agonism of 5-HT1A Somatodendritic Autoreceptors in the Dorsal Raphe Nucleus,” *British Journal of Pharmacology* 165, no. 8 (2012) : 2620–34, doi:10.1111/j.1476-5381.2011.01621.x.
- [105]E. M. Rock et al., “Cannabinoid Regulation of Acute and Anticipatory Nausea,” *Cannabis and Cannabinoid Research* 1, no. 1 (2016) : 113–21, doi:10.1089/can.2016.0006.
- [106]D. Bolognini et al., “Cannabidiolic Acid Prevents Vomiting InSuncus Murinusand Nausea-Induced Behaviour in Rats by Enhancing 5-HT1A Receptor Activation,” *British Journal of Pharmacology* 168, no. 6 (2013) : 1456–70, doi:10.1111/bph.12043.
- [107]L. D. O'Brien et al., “Anandamide Transport Inhibition by ARN272 Attenuates Nausea-Induced Behaviour in Rats, and Vomiting in Shrews (Suncus Murinus) ,” *British Journal of Pharmacology* 170, no. 5 (2013) : 1130–36, doi:10.1111/bph.12360.
- [108]Hilal Ahmad Parray and Jong Won Yun, “Cannabidiol Promotes Browning in 3T3-

- L1 Adipocytes," *Molecular and Cellular Biochemistry* 416, no. 1–2 (2016) : 131–39, doi:10.1007/s11010-016-2702-5.
- [109]Itay Lotan et al., "Cannabis (Medical Marijuana) Treatment for Motor and Non-Motor Symptoms of Parkinson Disease," *Clinical Neuroparmacology* 37, no. 2 (2014) : 41–44, doi:10.1097/wnf.000000000000016.
- [110]Sandeep Vasant More and Dong-Kug Choi, "Promising Cannabinoid-Based Therapies for Parkinson's Disease: Motor Symptoms to Neuroprotection," *Molecular Neurodegeneration* 10, (April 2015) : 17, doi:10.1186/s13024-015-0012-0.
- [111]Sandeep Vasant More and Dong-Kug Choi, "Emerging Preclinical Pharmacological Targets for Parkinson's Disease," *Oncotarget* 7, no. 20 (2016) : 29835–63, doi:10.18632/oncotarget.8104.
- [112]Marcos Hortes N. Chagas et al., "Effects of Cannabidiol in the Treatment of Patients with Parkinson's Disease: An Exploratory Double-Blind Trial," *Journal of Psychopharmacology* 28, no. 11 (2014) : 1088–98, doi:10.1177/0269881114550355.
- [113]Teresa Iuvone et al, "Cannabidiol: A Promising Drug for Neurodegenerative Disorders?" *CNS Neuroscience & Therapeutics* 15, no. 1 (2009) : 65-75, doi: 10.1111/j.1755-5949.2008.00065.x.
- [114]Rosaria Greco et al., "The Endocannabinoid System and Migraine," *Experimental Neurology* 224, no. 1 (2010) : 85–91, doi:10.1016/j.expneurol.2010.03.029.
- [115]Ethan B. Russo, "Cannabinoids in the Management of Difficult to Treat Pain," *Therapeutics and Clinical Risk Management* 4, no. 1 (2008) : 245–59, doi:10.2147/tcrm.s1928.
- [116]Kevin F. Boehnke, Evangelos Litinas, and Daniel J. Clauw, "Medical Cannabis Use Is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients with Chronic Pain," *The Journal of Pain* 17, no. 6 (2016) : 739–44, doi:10.1016/j.jpain.2016.03.002.
- [117]Ethan B. Russo and Andrea G Hohmann, "Role of Cannabinoids in Pain Management," Essay, In *Treatment of Chronic Pain by Medical Approaches*, (2013) : 181–97. New York, NY: Springer.
- [118]Jeremy R. Johnson et al., "Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain," *Journal of Pain and Symptom Management* 39, no. 2 (2009) : 167–79, doi:10.1016/j.jpainsymman.2009.06.008.
- [119]D. I. Abrams and M. Guzman, "Cannabis in Cancer Care," *Clinical Pharmacology and Therapeutics* 97, no. 6 (2015) : 575–86, doi:10.1002/cpt.108.
- [120]Jonathan L. C. Lee et al., "Cannabidiol Regulation of Emotion and Emotional Memory Processing: Relevance for Treating Anxiety-Related and Substance Abuse Disorders," *British Journal of Pharmacology* 174, no. 19 (2017) : 3242–56, doi:10.1111/bph.13724.
- [121]Chenchen Song, et al., "Bidirectional Effects of Cannabidiol on Contextual Fear Memory Extinction," *Frontiers in Pharmacology* 16, no. 7 (2016) , doi:10.3389/fphar.2016.00493.
- [122]Matthew N. Hill et al., "Reductions in Circulating Endocannabinoid Levels in Individuals with Post-Traumatic Stress Disorder Following Exposure to the World Trade Center Attacks," *Psychoneuroendocrinology* 38, no. 12 (2013) : 2952–61, doi:10.1016/j.psyneuen.2013.08.004.
- [123]Tabitha A. Iseger and Matthijs G. Bossong, "A Systematic Review of the Antipsychotic Properties of Cannabidiol in Humans," *Schizophrenia Research* 162, no. 1–3 (2015) : 153–

- 61, doi:10.1016/j.schres.2015.01.033.
- [124] A.W. Zuardi et al., "Cannabidiol, a Cannabis Sativa Constituent, as an Antipsychotic Drug," *Brazilian Journal of Medical and Biological Research* 39, no. 4 (2006) : 421–29, doi:10.1590/s0100-879x2006000400001.
- [125] Ethan B. Russo, "Clinical Endocannabinoid Deficiency (CECD) : Can This Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and Other Treatment-Resistant Conditions?" *Neuro Endocrinology Letters* 25, no. 1–2 (2004) : 31–39.
- [126] Chung Mo Koo and Hoon-Chul Kang, "Could Cannabidiol Be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?" *Journal of Epilepsy Research* 7, no. 1 (2017) : 16–20, doi:10.14581/jer.17003.
- [127] Margaret Gedde and Edward Maa, "Whole Cannabis Extract of High Concentration Cannabidiol May Calm Seizures in Highly Refractory Pediatric Epilepsies," *Realm of Caring, Realm of Caring Foundation*, March 2, 2016, <https://www.theroc.us/gedde-study>.
- [128] Shaun A. Hussain et al., "Perceived Efficacy of Cannabidiol-Enriched Cannabis Extracts for Treatment of Pediatric Epilepsy: A Potential Role for Infantile Spasms and Lennox–Gastaut Syndrome," *Epilepsy & Behavior* 47, (April 2015) : 138–41, doi:10.1016/j.yebeh.2015.04.009.
- [129] Emma H. Kaplan et al., "Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome," *Pediatric Neurology* 71, (June 2017) : 18–23, doi:10.1016/j.pediatrneurol.2017.02.009.
- [130] Evan C. Rosenberg Pabitra H. Patra, and Benjamin J. Whalley, "Therapeutic Effects of Cannabinoids in Animal Models of Seizures, Epilepsy, Epileptogenesis, and Epilepsy-Related Neuroprotection," *Epilepsy & Behavior* 70, Pt B (2017) : 319–27, doi:10.1016/j.yebeh.2016.11.006.
- [131] Thomas W. Klein and Catherine A. Newton, "Therapeutic Potential of Cannabinoid-Based Drugs," *Advances in Experimental Medicine and Biology Immune-Mediated Diseases* 601 (2007) : 395–413, doi:10.1007/978-0-387-72005-0_43.
- [132] M. Karsak et al., "Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System," *Science* 316, no. 5830 (2007) : 1494–97, doi:10.1126/science.1142265.
- [133] Attila Oláh et al., "Cannabidiol Exerts Sebostatic and Antiinflammatory Effects on Human Sebocytes," *Journal of Clinical Investigation* 124, no. 9 (2014) : 3713–24, doi:10.1172/jci64628.
- [134] Ethan B. Russo, "Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes," *Cannabis and Cannabinoid Research* 1, no. 1 (2016) : 154–65, doi:10.1089/can.2016.0009.
- [135] Jonathan D. Wilkinson and Elizabeth M. Williamson, "Cannabinoids Inhibit Human Keratinocyte Proliferation through a Non-CB1/CB2 Mechanism and Have a Potential Therapeutic Value in the Treatment of Psoriasis," *Journal of Dermatological Science* 45, no. 2 (2006) : 87–92, doi:10.1016/j.jdermsci.2006.10.009.
- [136] Daniel F. Kripke, "Hypnotic Drug Risks of Mortality, Infection, Depression, and Cancer: but Lack of Benefit," *F1000Research* 5, (May 2016) : 918, doi:10.12688/f1000research.8729.1.
- [137] Ethan B. Russo, "Cannabidiol Claims and Misconceptions," *Trends in Pharmacological Sciences* 38, no. 3 (2017) : 198–201, doi:10.1016/j.tips.2016.12.004.

- [138]Elisaldo A. Carlini and Jomar M. Cunha, "Hypnotic and Antiepileptic Effects of Cannabidiol," *The Journal of Clinical Pharmacology* 21, S1 (1981) , doi:10.1002/j.1552-4604.1981.tb02622.x.
- [139]Atheer Zgair et al., "Dietary Fats and Pharmaceutical Lipid Excipients Increase Systemic Exposure to Orally Administered Cannabis and Cannabis-Based Medicines," *American Journal of Translational Research* 8, no. 8 (2016) : 3448–59.
- [140]A. Hazekamp and J. T. Fischeidick, "Cannabis—from Cultivar to Chemovar," *Drug Testing and Analysis* 4, no. 7–8 (2012) : 660–67. doi:10.1002/dta.407.
- [141]G. C. Ceschel et al., "In Vitro Permeation through Porcine Buccal Mucosa of Salvia Desoleana Atzei & Picci Essential Oil from Topical Formulations," *International Journal of Pharmaceutics* 195, no. 1–2 (2000) : 171–77, doi:10.1016/s0378-5173 (99) 00381-6.
- [142]Attila Olah et al., "Cannabidiol Exerts Sebostatic and Antiinflammatory Effects on Human Sebocytes," *Journal of Clinical Investigation* 124, no. 9 (2014) : 3713–24, doi:10.1172/jci64628.
- [143]M. Jamontt et al., "The Effects of Δ 9-Tetrahydrocannabinol and Cannabidiol Alone and in Combination on Damage, Inflammation Andin Vitromotility Disturbances in Rat Colitis," *British Journal of Pharmacology* 160, no. 3 (2010) : 712–23, doi:10.1111/j.1476-5381.2010.00791.x.
- [144]Dustin Sulak, Russell Saneto, and Bonni Goldstein, "The Current Status of Artisanal Cannabis for the Treatment of Epilepsy in the United States," *Epilepsy & Behavior* 70, Pt B (2017) : 328–33, doi:10.1016/j.yebeh.2016.12.032.
- [145]Deepak Cyril D'Souza et al., "Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis," *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* 1, no. 1 (2016) : 60–67, doi:10.1016/j.bpsc.2015.09.008.